Publications

RECENT PUBLICATIONS

Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, Kaisho T, Bogunovic D, Bhardwaj N, Krummel MF. – Cancer Cell. 2016

Modulation of innate immunity in the tumor microenvironment.

Gonzalez-Gugel E, Saxena M, Bhardwaj N. – Cancer Immunol Immunother. 2016

Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N, Chakarov S, Rivera C, Hogstad B, Bosenberg M, Hashimoto D, Gnjatic S, Bhardwaj N, Palucka AK, Brown BD, Brody J, Ginhoux F, Merad M. – Immunity. 2016

CD4 Receptor is a Key Determinant of Divergent HIV-1 Sensing by Plasmacytoid Dendritic Cells.

O’Brien M, Manches O, Wilen C, Gopal R, Huq R, Wu V, Sunseri N, Bhardwaj N. – PLoS Pathog. 2016

Dendritic Cell Vaccines.

Sabado RL, Meseck M, Bhardwaj N. – Methods Mol Biol. 2016.

The Human Vaccines Project: A roadmap for cancer vaccine development.

Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G. – Sci Transl Med. 2016

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN). – J Immunother Cancer. 2016

In situ vaccination for the treatment of cancer.

Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. – Immunotherapy. 2016.

Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy.

Finnigan JP Jr, Rubinsteyn A, Hammerbacher J, Bhardwaj N. – Oncology (Williston Park). 2015.

Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells.

Tanne A, Muniz LR, Puzio-Kuter A, Leonova KI, Gudkov AV, Ting DT, Monasson R, Cocco S, Levine AJ, Bhardwaj N, Greenbaum BD. – Proc Natl Acad Sci U S A. 2015

Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cells.

Fernandez MV, Miller E, Krammer F, Gopal R, Greenbaum BD, Bhardwaj N. – J Leukoc Biol. 2016

AACR Cancer Progress Report 2015.

Baselga J, Bhardwaj N, Cantley LC, DeMatteo R, DuBois RN, Foti M, Gapstur SM, Hahn WC, Helman LJ, Jensen RA, Paskett ED, Lawrence TS, Lutzker SG, Szabo E. – Clin Cancer Res. 2015

Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial.

Gandhi RT, Kwon DS, Macklin EA, Shopis JR, McLean AP, McBrine N, Flynn T, Peter L, Sbrolla A, Kaufmann DE, Porichis F, Walker BD, Bhardwaj N, Barouch DH, Kavanagh DG. – J Acquir Immune Defic Syndr. 2016

Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection.

Miller EA, Gopal R, Valdes V, Berger JS, Bhardwaj N, O’Brien MP. – AIDS. 2015

Reversal of natural killer cell exhaustion by TIM-3 blockade.

Gallois A, Silva I, Osman I, Bhardwaj N. – Oncoimmunology. 2015

Cancer immunotherapy: dendritic-cell vaccines on the move.

Sabado RL, Bhardwaj N. – Nature. 2015

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.

Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg JD, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N. – Cancer Immunol Res. 2015.

Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.

Moskalenko M, Pan M, Fu Y, de Moll EH, Hashimoto D, Mortha A, Leboeuf M, Jayaraman P, Bernardo S, Sikora AG, Wolchok J, Bhardwaj N, Merad M, Saenger Y. – Cancer Immunol Res. 2015

Dendritic cells and lymphoma cells: come together right now.

Bhardwaj N, Brody JD. – Blood. 2015

Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy.

Moogk D, da Silva IP, Ma MW, Friedman EB, de Miera EV, Darvishian F, Scanlon P, Perez-Garcia A, Pavlick AC, Bhardwaj N, Christos PJ, Osman I, Krogsgaard M. – J Transl Med. 2014